European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) was established in 1993. Inaugurated in Lisbon in 1995, it is one of the EU’s decentralised agencies. The EMCDDA exists to provide the EU and its Member States with a factual overview of European drug problems and a solid evidence base to support the drugs debate. Today it offers policymakers the data they need for drawing up informed drug laws and strategies. It also helps professionals and practitioners working in the field pinpoint best practice and new areas of research.

Mission

The EMCDDA was set up to provide 'factual, objective, reliable and comparable information concerning drugs, drug addiction and their consequences'

Registration opens for European Drugs Winter and Summer Schools 2022

The EMCDDA and the University Institute of Lisbon (ISCTE-IUL) are pleased to open registration for two upcoming joint events in 2022: the European Drugs Winter School (EDWS) and the European Drugs Summer School (EDSS) The two-week online Winter School (14th to 25th of February 2022) prepares professionals and students to meet the complex policy challenges that face Europe and the World in the field of drugs. Teaching staff includes scientific experts from the European Monitoring

Synthetic cannabinoids in Europe – a review

Published by
EMCDDA
Publication Date

This report provides a technical review of the current body of knowledge regarding synthetic cannabinoids that are monitored by the the EU Early Warning System.

The aim of this report is to strengthen situational awareness of synthetic cannabinoids in Europe and to help stakeholders prepare for, and respond to, public health and social threats caused by such substances.

Increase access to hepatitis C (HCV) testing and care in drug services- a toolkit

Created by
EMCDDA

People who inject drugs (PWID) are a key population for the elimination of hepatitis C in Europe, and increasing their access to HCV testing and care is a goal in European and national hepatitis C policies. Despite this, HCV testing remains low among people who inject drugs and effective approaches to promote testing as the first element of a cascade of care are particularly needed.

Manual: increasing access to hepatitis C testing and care for people who inject drugs

Created by
EMCDDA
Publication Date
This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment for people who use drugs.